Gemina Laboratories Ltd. (C:GLAB)
Business Focus: Laboratory Diagnostic & Testing Substances
Apr 09, 2024 10:00 am ET
Gemina Labs Announces Addition to its IP Portfolio
VANCOUVER, BC / ACCESSWIRE /April 9, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") today announces that it has licensed a novel biosensing architecture from the University of British Columbia.
Apr 02, 2024 09:00 am ET
Gemina Laboratories Sign First Strategic License Agreement
VANCOUVER, BC / ACCESSWIRE / April 2, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the signing of a license agreement with a significant global diagnostics company. The license agreement is the culmination of Gemina's commercialization program to date and will enable our new licensing partner to develop, manufacture and sell new products using Gemina's IP platform.
Mar 21, 2024 09:00 am ET
Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships
VANCOUVER, BC / ACCESSWIRE / March 21, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide a strategic update and outlook for 2024 and beyond. The Company is beginning to see results from its 2023 focus on developing large scale commercial partnerships. Our emphasis on developing multiple revenue streams, including product development, licenses, and services, will improve our revenue visibility in the second half of this year. 2024 will see Gemina complete the buildout of ou
Mar 19, 2024 08:30 am ET
Gemina Announces Closing of $910,000 Convertible Note Financing
VANCOUVER, BC / ACCESSWIRE / March 19, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce that further to its news release dated February 22, 2024, it has raised gross proceeds of $910,000 under its non-brokered private placement (the "Private Placement") of unsecured convertible notes of the Company (the "Notes"). Please see the Company's news release dated February 22, 2024 for additional details regarding the terms o
Nov 06, 2023 08:00 am ET
Gemina Labs Ltd Appoints Stifel as Financial Advisor
VANCOUVER, BC / ACCESSWIRE / November 6, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7), a diagnostics technology company, is pleased to announce that it has appointed the global investment bank Stifel as its sole and exclusive financial advisor to the Company, as it considers strategic licensing and partnership opportunities for its breakthrough diagnostics technology.
Sep 19, 2023 03:48 pm ET
Canadian Securities Exchange Reports August 2023 Performance Figures
Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for August 2023.
Jul 25, 2023 08:00 am ET
Gemina Laboratories Announces Major Breakthrough in Environmentally Friendly Lateral Flow Test Design by Removing the Requirement for Nitrocellulose
VANCOUVER, BC / ACCESSWIRE / July 25, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is excited to announce another major innovation in lateral flow assay ("LFA") test design resulting from its innovative, patented Gemina Bridge chemistry platform. Gemina Labs has deployed cellulose (paper) test strips in the lateral flow assay format, a fully biodegradable, environmentally friendly alternative to the industry-standard nitrocellulose strip.
Jun 15, 2023 09:00 am ET
Gemina Laboratories to Participate in Poster Session at American Association of Clinical Chemistry Annual Scientific Meeting
Gemina to present achievement of another significant technical milestone.
Jun 05, 2023 08:00 am ET
Gemina Laboratories and ReadyGo Diagnostics Achieve Mycobacterium Tuberculosis Diagnosis in Saliva
VANCOUVER, BC / ACCESSWIRE / June 5, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7), a specialist in fast, affordable, and accurate diagnostic tests, is delighted to announce significant technical results from its collaboration with ReadyGo Diagnostics Ltd. ("ReadyGo"), an isothermal molecular diagnostics developer based in Bath, UK. This represents the first step of Gemina's move into molecular diagnostics adding further diagnostic capability to compliment our lateral flow programme.
May 17, 2023 09:15 am ET
Gemina Labs Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay Performance Improvement
VANCOUVER, BC / ACCESSWIRE / May 17, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is delighted to announce that its patented chemistry for Antibody Immobilization allows for a massive reduction in antibody usage when used in lateral flow assay ("LFA") diagnostic tests.
Mar 27, 2023 11:50 am ET
Gemina Laboratories to Host Investor Webinar on March 30, 2023
VANCOUVER, BC / ACCESSWIRE / March 27, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce that it will host a live investor webinar presentation on Thursday, March 30, 2023 at 2:00 PM ET. During the webcast, Brian Firth, CEO, will conduct a presentation that will cover key areas of Gemina's business. After the formal presentation, participants will have the opportunity to ask questions through an interactive Q&A portal. To listen to the webcast or to ask questions duri
Mar 07, 2023 08:00 am ET
Gemina Labs Appoints Diagnostic Strategist Martha Najib to the Board
VANCOUVER, BC / ACCESSWIRE / March 7, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is delighted to announce that it has appointed Martha Najib as an independent director of the Company.
Jan 25, 2023 08:00 am ET
Gemina Labs Announces Appointment of Healthcare Industry Leader Dr. Bola Grace to The Board of Directors
VANCOUVER, BC / ACCESSWIRE / January 25, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is delighted to announce the appointment of Dr. Bola Grace to the Board of Directors.
Jan 23, 2023 08:00 am ET
Gemina Labs Appoints Top Ranked UK Analyst and Scientist, Dr. Stefan Hamill as Vice President, Strategy
VANCOUVER, BC / ACCESSWIRE / January 23, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is delighted to announce that it has appointed Dr. Stefan Hamill as Vice President, Strategy of the Company.
Jan 10, 2023 02:55 pm ET
Gemina Labs Strategic Update: Respiratory Infections the Immediate Focus and New Strategic Partnerships on the Horizon
VANCOUVER, BC / ACCESSWIRE / January 10, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide the following strategic overview and share an outlook for 2023 and beyond. The Company enters 2023 at a significant inflection point in its growth, maturing from its primary focus on R&D and proof of concept work, to the development of large-scale commercial partnerships and opportunities. The Company has narrowed its core development focus to the area of respiratory diagnostics,
Jan 06, 2023 11:20 am ET
Gemina Labs Completes Influenza A/B Diagnostic Test Prototype
VANCOUVER, BC / ACCESSWIRE / January 6, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the completion of its influenza A/B rapid test prototype. The Company announced its intention to develop an influenza diagnostic in Q2 of 2022, using Gemina's unique chemistry platform.
Dec 20, 2022 08:00 am ET
Gemina Labs Appoints Dr Michael Shannon as Chair of Clinical Advisory Board
VANCOUVER, BC / ACCESSWIRE / December 20, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is delighted to announce Dr. Michael Shannon has been appointed to constitute and Chair the Company's Clinical Advisory Board.
Dec 19, 2022 12:30 pm ET
Gemina Labs Announces Research Collaboration on Next Generation Biosensors
VANCOUVER, BC / ACCESSWIRE / December 19, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce that it has entered into a collaborative research partnership focused on the development of wearable biosensors with Dr. Amanda Clifford at the University of British Columbia.
Dec 13, 2022 11:40 am ET
Gemina's Recent Investment into RAPIvD Sees Immediate Progress
VANCOUVER, BC / ACCESSWIRE / December 13, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce that RAPIvD Limited ("RAPIvD") has met an important regulatory milestone.
Dec 07, 2022 11:30 am ET
Gemina Labs Announces Strategic Stake in British Rapid Test Optimizer Rapivd Limited
VANCOUVER, BC / ACCESSWIRE / December 7, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce that the Company has entered into a definitive share exchange agreement (the "Definitive Agreement") with RAPIvD Limited ("RAPIvD") and the holders (the "RAPIvD Shareholders") of the ordinary shares of RAPIvD (the "RAPIvD Shares"). Pursuant to the Definitive A
Oct 06, 2022 12:10 pm ET
Gemina Labs Enters into Licence and Manufacturing Agreements
VANCOUVER, BC / ACCESSWIRE / October 6, 2022 / Gemina Laboratories Ltd. (CSEGLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce that it has entered into agreement with International Point of Care, Inc ("IPOC"), for the manufacturing of its Legio XTM COVID-19 Rapid Antigen Test (the "Legio XTM Test"). The agreements signed today include both a Manufacturing and Supply Agreement and a License Agreement setting out the terms upon which IPOC will manufacture the Legio X
Sep 12, 2022 09:20 am ET
Gemina Labs Presents at the H.C. Wainwright Global Investment Conference
VANCOUVER, BC / ACCESSWIRE / September 12, 2022, / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7) (US:OTC GLABF) (the "Company" or "Gemina") is pleased to announce its participation both virtually and in person at the H.C. Wainwright 24th Annual Global Investment Conference. Gemina's presentation hosted by CEO Brian Firth, will be available for viewing on Monday September 12, 2022, beginning at 7:00 a.m. EST. Mr. Firth will also be attending the live event and available for one on one meetings.
Sep 06, 2022 11:45 am ET
Gemina Labs Appoints Diagnostic Executive Brian Firth as Chief Executive Officer
VANCOUBVER, BC / ACCESSWIRE / September 6, 2022 / Gemina Laboratories Ltd. (CSE:GLAB) (FRA:8I7) (US:OTC:GLABF) (the "Company" or "Gemina") is excited to announce the appointment of Brian Firth, an accomplished diagnostic industry executive, as the Company's new Chief Executive Officer. Gemina is also pleased to announce the appointment of founding CEO John Davies, as Chairman of the Board of Directors. The appointment of Mr. Firth follows a multi month process initiated by the Board and current executive team to identify ca
Jul 11, 2022 07:45 pm ET
Gemina Labs Announces Closing Of Concurrent Private Placement
VANCOUVER, BC / ACCESSWIRE / July 11, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the closing of its previously announced non-brokered private placement (the "Private Placement"), raising gross proceeds of $921,720 through the issuance of 1,536,200 units (the "Units") at a price of $0.60 per Unit. Each Unit consists of one common share (a "Common Share") of Gemina and o
Jun 30, 2022 03:40 pm ET
Gemina Announces Closing Of Prospectus Supplement Offering And Update To Concurrent Non-brokered Private Placement
VANCOUVER, BC / ACCESSWIRE / June 30, 2022 / Gemina Laboratories Ltd. (the "Company" or "Gemina") (CSE:GLAB)(FRA:8I7) is pleased to announce that the Company has closed its previously announced "commercially reasonable best efforts" offering by way of prospectus supplement (the "Offering"). Pursuant to the Offering, the Company issued 5,626,735 units of the Company ("Units") at a price of $0.60 per Unit (the "Unit Price") for aggregat
Jun 24, 2022 08:00 am ET
Gemina Announces Filing of Prospectus Supplement
VANCOUVER, BC / ACCESSWIRE / June 24, 2022 / Gemina Laboratories Ltd. (the "Company" or "Gemina") (CSE:GLAB)(FRA:8I7) is pleased to announce that the Company has entered into an agency agreement dated June 23, 2022 (the "Agency Agreement") with Leede Jones Gable Inc. (the "Agent"). Pursuant to the Agency Agreement, the Company proposes to complete a "commercially reasonable best efforts" offering by way of prospectus supplement to the Company's base shelf prosp
Jun 21, 2022 04:50 pm ET
Gemina Announces Proposed Financing Up to $5 Million
VANCOUVER, BC / ACCESSWIRE / June 21, 2022 / Gemina Laboratories Ltd. (the "Company" or "Gemina") (CSE:GLAB) (FRA:8I7) is pleased to announce that the Company has engaged Leede Jones Gable Inc., as agent, (the "Agent") to offer, on a commercially reasonable best efforts basis (the "Financing"), up to 8,334,000 units of the Company ("Units") at a price of $0.60 per Unit (the "Unit Price") for aggregate gross proceeds of up to $5,000,400 (the "Financing Proceeds"). The Company has agreed to grant the Agent an
Jun 08, 2022 08:00 am ET
Gemina Labs Appoints Point-of-Care Diagnostic Executive Brian Firth as Advisor
VANCOUVER, BC / ACCESSWIRE / June 8, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the appointment of Brian Firth as an adviser to the Company.
May 17, 2022 08:30 am ET
Gemina Labs Announces CE Mark for its First Product - The Best in Class Legio-X COVID Rapid Antigen Test
VANCOUVER, BC / ACCESSWIRE / May 17, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce that its inaugural product - the Gemina Legio XTM COVID-19 Rapid Antigen Test - has been awarded an EU CE Mark under the EU's In Vitro Diagnostic Medical Device Directive ("IVDD"). The CE Mark signifies that a product sold in the European Union has been assessed to meet high safety, health, and environmental protection requirements, and for business
May 05, 2022 08:30 am ET
Gemina Labs Completes Successful Human Clinical Performance Evaluation on its Legio X COVID-19 Rapid Antigen Test
VANCOUVER, BC / ACCESSWIRE / May 5, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the successful completion of its human performance study for the Gemina Legio XTM COVID-19 Rapid Antigen test, a significant development milestone demonstrating the power of Gemina's novel patented chemistry.
Apr 28, 2022 08:30 am ET
Gemina Labs Nears Completion of Phase 2 Human Patient Testing for Initial Diagnostic Test
With extremely encouraging results in hand from its Phase 1 work with International Point of Care ("IPOC"), Gemina Labs moved into Phase 2 development work on its COVID-19 platform with human subjects. A clinical performance study with prospectively collected patient samples was initiated in early April 2022 at Centro Diagnostico Buonarroti in Civitavecchia, Italy. The Buonarroti Diagnostic Centre is a leading health facility with expertise in the provision of diagnostic testing and clinical analysis for Italy's general population, with a specific expertise in COVID-19 testing. Three
Mar 31, 2022 09:00 am ET
Gemina Labs Provides Technical Development Update for Initial Diagnostic Test and Reports Filing of New IP
VANCOUVER, BC / ACCESSWIRE / March 31, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide recent development updates for its initial diagnostic test targeting the COVID-19 virus. Since achieving the previously announced design freeze stage of the Gemina COVID-19 test, preliminary cross-reactivity testing has been completed against seasonal human coronaviruses 229E, OC43, and NL63 as well as influenza A and B. We are pleased to report that no cross-reactivit
Feb 23, 2022 10:50 am ET
Gemina Labs Establishes UK Subsidiary And Appoints David Browning As Head Of Productization
VANCOUVER, BC / ACCESSWIRE / February 23, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the formation of a wholly owned UK Subsidiary, Gemina Laboratories (UK) Limited, and the appointment of David Browning as Head of Productization.
Feb 15, 2022 10:45 am ET
Gemina Labs Strategic Update: From Product to Platform, Gemina Provides a Technology Roadmap
VANCOUVER, BC / ACCESSWIRE / February 15, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide the following strategic overview and share an outlook for 2022 and beyond.
Feb 03, 2022 08:45 am ET
Gemina Labs Announces Completion of Significant Development Step for its SARS-CoV-2 Rapid Test
VANCOUVER, BC / ACCESSWIRE / February 3, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide an update on its current activities related to the development of its first rapid diagnostic test targeting the SARS CoV-2 antigen, using the Company's patented breakthrough chemistry platform. Following the previously announced prototype design freeze for use in saliva and the transfer of the prototype to International Point of Care ("
Nov 18, 2021 09:00 am ET
Gemina Labs Announces Appointment Of Senior Scientific Adviser
VANCOUVER, BC / ACCESSWIRE / November 18, 2021 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the appointment of Professor Michael Catt as Senior Scientific Adviser to the Company.
Oct 25, 2021 08:30 am ET
Gemina Labs Announces Closing of Oversubscribed Private Placement
VANCOUVER, BC / ACCESSWIRE / October 25, 2021 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the closing of its previously announced CAD$2,000,000 non-brokered private placement (the "Placement").
Oct 20, 2021 12:15 pm ET
Gemina Labs Announces Private Placement
The net proceeds of the Offering, along with existing funds, will be deployed towards the ongoing development, manufacturing and final regulatory review of the Company's initial rapid diagnostic test using our breakthrough proprietary chemistry. Additionally, it will be applied to ongoing research and development work related to new diagnostics tests already in process, as well as general working capital. The securities issued under the Offering will be subject to a statutory hold period in Canada expiring four months and one day from the Closing Date.
Sep 20, 2021 02:25 pm ET
Gemina Labs Receives Positive Initial Manufacturing Results for SARS-CoV-2 Diagnostic Test
VANCOUVER, BC / ACCESSWIRE / September 20, 2021 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide an update on its current activities related to the development of its first rapid diagnostic test targeting the SARS CoV-2 antigen, using the Company's patented breakthrough chemistry. The results represent a significant milestone on the path to manufacturing Gemina's first diagnostic test and demonstrates the power of Gemina's chemistry in its ability to effectively test at lower
Sep 13, 2021 02:30 pm ET
Gemina Labs Provides Research and Development and Corporate Update
VANCOUVER, BC / ACCESSWIRE / September 13, 2021 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide an update on its research and development ("R&D") activities and highlight both recent and forthcoming milestones within the R&D group as well as our corporate development initiatives.
Aug 30, 2021 12:40 pm ET
Gemina Labs Announces Research and Development Appointments
VANCOUVER, BC / ACCESSWIRE / August 30, 2021 / Gemina Laboratories Ltd. (CSE:GLAB) (the "Company" or "Gemina") is pleased to announce several key hires within our Research and Development team.
Aug 10, 2021 05:17 pm ET
Gemina Labs Announces Listing on the Canadian Securities Exchange
VANCOUVER, BC / ACCESSWIRE / August 10, 2021 / Gemina Laboratories Ltd. (CSE:GLAB) (the "Company" or "Gemina") is pleased to announce that the common shares of the Company have begun trading on the Canadian Securities Exchange (the "CSE") at the open of trading on August 10, 2021 under the trading symbol "GLAB."
Aug 09, 2021 01:12 pm ET
CSE Bulletin: New Listing - Gemina Laboratories Ltd. (GLAB)
Toronto, Ontario--(Newsfile Corp. - Le 9 août/August 2021) The common shares of Gemina Laboratories Ltd. have been approved for listing on the CSE.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.